Effects of Electrogenetherapy with p53wt Combined with Cisplatin on Survival of Human Tumor Cell Lines with Different p53 Status

DNA and Cell Biology

Volumn 22, Issue 12, 2003, Pages 765-775

  Cemazar, Maja ^a   Grosel, Alenka ^a   Glavac, Damjan ^b   Kotnik, Vladimir ^c   Skobrne, Mojca ^c   Kranjc, Simona ^a   Mir, Lluis M ^d   Andre, Frank ^d   Opolon, Paule ^d   Sersa, Gregor ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

^b INSTITUTE OF PATHOLOGY   (Slovenia)

^c UNIVERSITY OF LJUBLJANA   (Slovenia)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PROTEIN P53; PROTEIN P53WT; UNCLASSIFIED DRUG;

ARTICLE; CELL KILLING; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; ELECTROPORATION; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE MUTATION; GENE THERAPY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CARCINOMA; VIRAL GENE THERAPY; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL SURVIVAL; CISPLATIN; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; ELECTROPORATION; GENE THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; LUMINESCENT PROTEINS; MALE; MICE; MICE, NUDE; MUTATION; PROSTATIC NEOPLASMS; SURVIVAL RATE; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 9144241829     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/104454903322624975     Document Type: Article

References (48)

1. BAKER, S.J., MARKOWITZ, S., FEARON, E.R., WILLSON, J.K., and VOGELSTEIN, B. (1990). Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249, 912-915.
2. BROWN, J.M., and WOUTERS, B.G. (1999). Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 59, 1391-1399.
3. BULLER, R.E., RUNNEBAUM, I.B., KARLAN, B.Y., HOROWITZ, J.A., SHAHIN, M., PETRAUSKAS, S., KREIENBERG, R., SLAMON, D., PEGRAM, M., and BUEKERS, T. (2002). A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther. 7, 553-566.
4. BULLOCK, A., and FERSHT, A. (2001). Rescuing the function of mutant p53. Nat. Rev. Cancer 1, 68-76.
5. CEMAZAR, M., SERSA, G., WILSON, J., TOZER, G.M., HART, S.L., GROSEL, A., and DACHS, G.U. (2002). Effective gene transfer to solid tumors using different non-viral gene delivery techniques: Electroporation, liposomes, and integrin-targeted vector. Cancer Gene Ther. 9, 399-406.
6. CICHON, T., JAMROZY, L., GLOGOWSKA, J., MISSOL-KOLKA, E., and SZALA, S. (2002). Electrotransfer of gene encoding endostatin into normal and neoplastic mouse tissues: Inhibition of primary tumor growth and metastatic spread. Cancer Gene Ther. 9, 771-777.
7. CLAYMAN, G.L., EL-NAGGAR, A.K., LIPPMAN, S.M., HENDERSON, Y.C., FREDERICK, M., MERRITT, J., ZUMSTEIN, L.A., TIMMONS, T.M., LIU, T.J., GINSBERG, L., et al (1998). Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J. Clin. Oncol. 12, 3155-3157.
8. CLAYMAN, G.L., FRANK, D.K., BRUSO, P.A., and GOEPFERT, H. (1999). Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin. Cancer Res. 5, 1715-1722.
9. DOLIVET, G., MERLIN, J.L., BARBERI-HEYOB, M., RAMACCI, C., ERBACHER, P., PARACHE, R.M., BEHR, J.P., and GUILLEMIN, F. (2002). In vivo growth inhibitory effect of iterative wild-type p53 gene transfer in human head and neck carcinoma xenografts using glucosylated polyethylenimine nonviral vector. Cancer Gene Ther. 8, 708-714.
10. EASTHAM, J.A., GRAFTON, W., MARTIN, C.M., and WILLIAMS, B.J. (2000). Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer. J. Urol., 164, 814-819.
11. GALANIS, E., and RUSSELL, S. (2001). Cancer gene therapy clinical trials: Lessons for the future. Br. J. Cancer 85, 1432-1436.
12. GEHL, J. (2003). Electroporation: Theory and methods, perspectives for drug delivery, gene therapy and research. Acta Physiol. Scand. 177, 437-447.
13. GILBERT, R., JAROSZESKI, M.J., HELLER, L., and HELLER, R. (2002). Electric field enhanced plasmid delivery to liver hepatocellular carcinomas. Technol. Cancer Res. Treat. 5, 355-364.
14. GOLZIO, M., TEISSIE, J., and ROLS, M.P. (2002). Direct visualization at the single-cell level of electrically mediated gene delivery. Proc. Natl. Acad. Sci. USA 99, 1292-1297.
15. GOTO, T., NISHI, T., TAMURA, T., DEV, S.B., TAKESHIMA, H., KOCHI, M., YOSHIZATO, K., KURATSU, J., SAKATA, T., HOFMANN, G.A., et al. (2000). Highly efficient electro-gene therapy of solid tumor by using an expression plasmid for the herpes simplex virus thymidine kinase gene. Proc. Natl. Acad. Sci. USA 97, 354-359.
16. HELLER, L., POTTINGER, C., JAROSZESKI, M.J., GILBERT, R., and HELLER, R. (2000). In vivo electroporation of plasmids encoding GM-CSF or interleukin-2 into existing B16 melanomas combined with electrochemotherapy induces long-term antitumour immunity. Melanoma Res. 10, 577-583.
17. HOLLSTEIN, M., SIDRANSKY, D., VOGELSTEIN, B., and HARRIS, C.C. (1991). p53 mutations in human cancers. Science 253, 49-53.
18. JAROSZESKI, M.J., HELLER, R., and GILBERT, R. (2000). Electrochemotherapy, electrogenetherapy and transdermal drug delivery. Clifton, NJ: Humana Press.
19. KUBALL, J., WEN, S.F., LEISSNER, J., ATKINS, D., MEINHARDT, P., QUIJANO, E., ENGLER, H., HUTCHINS, B., MANEVAL, D.C., GRACE, M.J., et al. (2002). Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. J. Clin. Oncol. 20, 957-965.
20. LANG, F.F., BRUNER, J.M., FULLER, G.N., ALDAPE, K., PRADOS, M.D., CHANG, S., BERGER, M.S., MCDERMOTT, M.W., KUNWAR, S.M., JUNCK, L.R., et al. (2003). Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: Biological and clinical results. J. Clin. Oncol. 21, 2508-2518.
21. LI, S., ZHANG X., XIA, X., ZHOU, L., BREAU, R., SUEN, J., and HANNA, E. (2001). Intramuscular electroporation delivery of IFN-alpha gene therapy for inhibition of tumour growth located at a distant site. Gene Ther. 8, 400-407.
22. LOHR, F., LO, D.Y., ZAHAROFF, D.A., HU, K., ZHANG, X., LI, Y., ZHAO, Y., DEWHIRST, M.W., YUAN, F., and LI, C.Y. (2001). Effective tumor therapy with plasmid-encoded cytokines combined with in vivo electroporation. Cancer Res. 61, 3281-3284.
23. MAKOWER, D., ROZENBLIT, A., KAUFMAN, H., EDELMAN, M., LANE, M.E., ZWIEBEL, J., HAYNES, H., and WADLER, S. (2003). Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin. Cancer Res. 9, 693-702.
24. MATSUBARA, H., MAEDA, M., GUNJI, Y., KOIDE, Y., ASANO, T., OCHIAI, T., SAKIYAMA, S., and TAGAWA, M. (2001). Combinatory anti-tumor effects of electroporation-mediated chemotherapy and wild-type p53 gene transfer to human esophageal cancer cells. Int. J. Oncol. 18, 825-829.
25. MIYAKE, H., HARA, I., GOHJI, K., YAMANAKA, K., ARAKAWA, S., and KAMIDONO, S. (1998). Enhancement of chemosensitivity in human bladder cancer cells by adenoviral-mediated p53 gene transfer. Anticancer Res. 18, 3087-3092.
26. MIKATA, K., UEMURA, H., OHUCHI, H., OHTA, S., NAGASHIMA, Y., and KUBOTA, Y. (2002). Inhibition of growth of human prostate cancer xenograft by transfection of p53 gene: Gene transfer by electroporation. Mol. Cancer Ther. 1, 247-252.
27. NARIMATSU, M., NAGAYAMA, Y., AKINO, K., YASUDA, M., YAMAMOTO, T., YANG, T.T., OHTSURU, A., NAMBA, H., YAMASHITA, S., AYABE, H., et al. (1998). Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplastic thyroid carcinoma cell line. J. Clin. Endocrinol. Metab. 83, 3668-3672.
28. NEMUNAITIS, J., GANLY, I., KHURI, F., ARSENEAU, J., KUHN, J., MCCARTY, T., LANDERS, S., MAPLES, P., ROMEL, L., RANDLEV, B., et al. (2000a). Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial. Cancer Res. 60, 6359-6366.
29. NEMUNAITIS, J., SWISHER, S.G., TIMMONS, T., CONNORS, D., MACK, M., DOERKSEN, L., WEILL, D., WAIT, J., LAWRENCE, D.D., KEMP, B.L., et al. (2000b). Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung Cancer. J. Clin. Oncol., 18, 609-622.
30. NEUMANN, E., and ROSENHECK, K. (1972). Permeability changes induced by electric impulses in vesicular membranes. J. Membr. Biol. 10, 279-290.
31. NGUYEN, D., SPITZ, F., YEN, N., CRISTIANO, R., and ROTH, J. (1996). Gene therapy for lung cancer: Enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J. Thorac. Cardiovasc. Surg. 112, 1372-1377.
32. NIELSEN, L.L., and MANEVAL, D.C. (1998). P53 tumor suppressor gene therapy for cancer. Cancer Gene Ther. 5, 52-63.
33. NIU, G., HELLER, R., CATLETT-FALCONE, R., COPPOLA, D., JAROSZESKI, M., DALTON, W., JOVE, R., and YU, H. (1999). Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res. 59, 5059-5063.
34. O'CONNOR, P.M., JACKMAN, J., BAE, I., MYERS, T.G., FAN, S., MUTOH, M., SCUDIERO, D.A., MONKS, A., SAUSVILLE, E.A., WEINSTEIN, J.N., et al. (1997). Characterization of the p53 tumour suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 57, 4285-4300.
35. PAGLIARO, L.C., KEYHANI, A., WILLIAMS, D., WOODS, D., LIU, B., PERROTTE, P., SLATON, J.W., MERRITT, J.A., GROSSMAN, H.B., and DINNEY, C.P. (2003). Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: A phase I study of p53 gene therapy. J. Clin. Oncol. 21, 2247-2253.
36. PUC, M., FLISAR, K., REBERSEK, S., and MIKLAVCIC, D. (2001). Electroporator for in vitro cell permeabilization. Radiol. Oncol. 35, 203-207.
37. ROLS, M.P., DELTEIL, C., GOLZIO, M., DUMOND, P., CROS, S., and TEISSIE, J. (1998). In vivo electrically mediated protein and gene transfer in murine melanoma. Nat. Biotechnol. 16, 168-171.
38. ROTH, J.A., NGUYEN, D., LAWRENCE, D.D., KEMP, B.L., CARRASCO, C.H., FERSON, D.Z., HONG, W.K., KOMAKI, R., LEE, J.J., NESBITT, J.C., et al. (1996). Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat. Med. 2, 985-991.
39. ROTH, J.A., SWISHER, S.G., and MEYN, R.E. (1999). p53 tumor suppressor gene therapy for cancer. Oncology (Huntingt) 13, 148-154.
40. RUBIN, S.J., HALLAHAN, D.E., ASHMAN, C.R., BRACHMAN, D.G., BECKETT, M.A., VIRUDACHALAM, S., YANDELL, D.W., and WEICHSELBAUM, R.R. (1991). Two prostate carcinoma cell lines demonstrate abnormalities in tumour suppressor genes. J. Surg. Oncol. 46, 31-36.
41. SERSA, G., CEMAZAR, M., and RUDOLF, Z. (2003). Electrochemotherapy: Advantages and drawbacks in treatment of cancer patients. Cancer Ther. 1, 133-142.
42. SHIBATA, M., MORIMOTO, J., and OTSUKI, Y. (2002). Suppression of murine mammary carcinoma growth and metastasis by HSVtk/GCV gene therapy using in vivo electroporation. Cancer Gene Ther. 1, 16-27.
43. SHONO, T., TOFILON, P.J., SCHAEFER, T.S., PARIKH, D., LIU, T.J., and LANG, F.F. (2002). Apoptosis induced by adenovirus-mediated p53 gene transfer in human glioma correlates with site-specific phosphorylation. Cancer Res. 62, 1069-1076.
44. SWISHER, S.G., ROTH, J.A., KOMAKI, R., GU, J., LEE, J.J., HICKS, M., RO, J.Y., HONG, W.K., MERRITT, J.A., AHRAR, K., et al. (2003). Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin. Cancer Res. 9, 93-101.
45. TAMURA, T., NISHI, T., GOTO, T., TAKESHIMA, H., USHIO, Y., and SAKATA, T. (2003). Combination of IL-12 and IL-18 of electro-gene therapy synergistically inhibits tumor growth. Anticancer Res. 2b, 1173-1179.
46. VINYALS, A., PEINADO, M., GONZALEZ-GARRIGUES, M., MONZO, M., BONFIL, R. and FABRA, A. (1999). Failure of wild-type p53 gene therapy in human cancer cells expressing a mutant p53 protein. Gene Ther. 6, 22-33.
47. YANG, C., CIRIELLI, C., CAPOGROSSI, M.C., and PASSANITI, A. (1995). Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res. 55, 4210-4213.
48. ZEIMET, A.G., RIHA, K., BERGER, J., WIDSCHWENDTER, M., HERMANN, M., DAXENBICHLER, G., and MARTH, C. (2000). New insights into p53 regulation and gene therapy for cancer. Biochem. Pharmacol. 8, 1153-1163.